![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Allergan to Pay $200 Million to Settle New York Opioid Lawsuit
Allergan to Pay $200 Million to Settle New York Opioid Lawsuit
December 10, 2021
Allergan has agreed to pay $200 million to resolve New York-based claims that it helped facilitate the state’s opioid crisis through deceptive marketing.
The agreement earmarks more than $150 million for addressing harm caused by opioid addiction, stipulating the money must be paid by mid-2022, and bars Allergan from selling opioid products in the future.
The settlement marks Allergan’s withdrawal from the ongoing trial in the Suffolk County State Supreme Court, leaving Teva Pharmaceuticals as the sole defendant in New York’s litigation to hold opioid makers accountable for allegedly fueling the epidemic.
Closing arguments were held Wednesday and the jury must now reach a verdict.
Upcoming Events
-
21Oct